{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265841","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-06-10T20:12:16+00:00","discovered_at":"2026-06-10T20:13:00.223115+00:00","generated_at":"2026-06-10T20:16:55.885306+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Rapport Therapeutics stockholders elect three Class II directors and ratify PwC as auditor","bullets":["James Healy, M.D., Ph.D. elected with 41,762,713 for, 587,163 withheld; broker non-votes 1,983,035.","Robert J. Perez elected with 37,592,089 for, 4,757,787 withheld; Raymond Sanchez with 41,754,131 for, 595,745 withheld.","Ratification of PricewaterhouseCoopers as independent auditor passed: 44,255,547 for, 57,445 against, 19,919 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265841","json":"https://secwatch.observer/filing/0001193125-26-265841.json","markdown":"https://secwatch.observer/filing/0001193125-26-265841.md","text":"https://secwatch.observer/filing/0001193125-26-265841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/0001193125-26-265841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/rapp-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:16:55.885306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1371a8ddb54438b48acc567d8c7fd875c9d5da67","claim":"Rapport Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of Proposal 2 were as follows: For Against Abstain 44,255,547 57,445 19,919","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/0001193125-26-265841-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"6966592487a52405e0995db261c18adc665360b1","claim":"Rapport Therapeutics, Inc. shareholders approved Election of Class II directors: James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 1 - Election of Class I Director Nominees The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows: Class II Director Nominee For Withheld Broker Non-Votes James Healy, M.D., Ph.D. 41,762,713 587,163 1,983,035 Robert J. Perez 37,592,089 4,757,787 1,983,035 Raymond Sanchez, M.D. 41,754,131 595,745 1,983,035","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/0001193125-26-265841-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}